CELG


Company Update (NASDAQ:CELG): Phase II Data for Celgene’s Investigational Oral GED-0301 for Patients with Active Crohn’s Disease Published in New England Journal of Medicine

Celgene Corporation (NASDAQ:CELG) today announced that results from a double-blind, placebo-controlled, multicenter phase II trial of three doses of GED-0301 (mongersen) in patients with …

UPDATE: Canaccord Maintains Buy On Celgene Corporation Following EU Approval For Revlimid

In a research report published Friday, Canaccord Genuity analyst John Newman maintained a Buy rating on Celgene Corporation (NASDAQ:CELG) with a price target …

Piper Jaffray Remains Bullish On Celgene Corporation Following 4Q14 Results

Piper Jaffray’s healthcare analyst Joshua Schimmer weighed in with an update on Celgene Corporation (NASDAQ:CELG), as the company reported yesterday morning full fourth-quarter results and guidance. The analyst …

CELG: Celgene Reports Fourth Quarter and Full Year 2014 Operating and Financial Results

(BUSINESS WIRE)– Celgene Corporation (NASDAQ:CELG) reported operating results for the fourth quarter and full year of 2014. For the fourth quarter of 2014, …

Stock Update (NASDAQ: CELG): Celgene Receives Positive CHMP Opinion for ABRAXANE® for First-Line Treatment of Patients with Non-Small Cell Lung Cancer

(BUSINESS WIRE)– Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that the European Medicines Agency’s (EMA) Committee for …

Company Update (NASDAQ:CELG):Oral OTEZLA® (apremilast) Approved by the European Commission for the Treatment of both Patients with Psoriasis and Psoriatic Arthritis

(BUSINESS WIRE)– Celgene International Sàrl (NASDAQ:CELG), a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission (EC) has granted marketing authorisation …

CELG: Celgene Corporation Announces 2015 and Long-Term Financial Outlook and Preliminary 2014 Results

(BUSINESS WIRE)– Celgene Corporation (NASDAQ:CELG) provided a business update as well as its preliminary 2014 results and financial outlook for 2015 and beyond …

J.P. Morgan Remains On The Sidelines On Celgene; Waits For Additional Drivers Of Near-Term Upside

In a research report published today, J.P.

Cowen Maintains Outperform On Celgene Following ASH Meeting; Keeps $110 PT

Cowen analyst Eric Schmidt maintained an Outperform rating on Celgene Corporation (NASDAQ:CELG) with a price target of $110, which, surprisingly, represents a potential …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts